{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T10:02:42Z","timestamp":1794650562407,"version":"4.9.1"},"reference-count":57,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"UK Research and Innovation Medical Research Council","doi-asserted-by":"publisher","award":["MR\/M015831\/1"],"award-info":[{"award-number":["MR\/M015831\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000765","name":"University College London","doi-asserted-by":"publisher","award":["UCL\/14\/0453"],"award-info":[{"award-number":["UCL\/14\/0453"]}],"id":[{"id":"10.13039\/501100000765","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jcyt.2026.102101","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T01:08:44Z","timestamp":1770253724000},"page":"102101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["A first-in-human phase I clinical trial investigating the safety and efficacy of repeat dosing MSCTRAIL cell therapy in addition to chemotherapy and immunotherapy in patients with advanced lung cancer"],"prefix":"10.1016","volume":"28","author":[{"given":"Rebecca N.","family":"Graham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0133-8826","authenticated-orcid":false,"given":"Monica L.","family":"Mullin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8713-0439","authenticated-orcid":false,"given":"Alexander G.","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9993-2523","authenticated-orcid":false,"given":"Ben","family":"Weil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Benafif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0462-7883","authenticated-orcid":false,"given":"Chuen Ryan","family":"Khaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh","family":"Selway-Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilyana","family":"Popova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0504-4937","authenticated-orcid":false,"given":"Sarah K.","family":"Howlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9473-2795","authenticated-orcid":false,"given":"Sevasti","family":"Galani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Szmul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Riddell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew G.","family":"Krebs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tammy","family":"Kalber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratima","family":"Chowdary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne L.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Sage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3254-5991","authenticated-orcid":false,"given":"Graham","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna","family":"Kolluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2600-5024","authenticated-orcid":false,"given":"Mark W","family":"Lowdell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin D.","family":"Forster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam M.","family":"Janes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jcyt.2026.102101_bib0001","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"10.1016\/j.jcyt.2026.102101_bib0002","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1158\/1055-9965.EPI-19-0221","article-title":"Cancer progress and priorities: lung cancer","volume":"28","author":"Schabath","year":"2019","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"6","key":"10.1016\/j.jcyt.2026.102101_bib0003","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1136\/thoraxjnl-2012-202297","article-title":"Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004\u20132007","volume":"68","author":"Walters","year":"2013","journal-title":"Thorax"},{"issue":"12","key":"10.1016\/j.jcyt.2026.102101_bib0004","doi-asserted-by":"crossref","first-page":"9640","DOI":"10.3390\/curroncol29120757","article-title":"Characterizing regional variability in lung cancer outcomes across Ontario: a population-based analysis","volume":"29","author":"Mullin","year":"2022","journal-title":"Curr Oncol"},{"issue":"3","key":"10.1016\/j.jcyt.2026.102101_bib0005","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.3390\/curroncol29030150","article-title":"Non-small-cell lung cancer in 2022: a review for general practitioners in oncology","volume":"29","author":"Mithoowani","year":"2022","journal-title":"Curr Oncol"},{"key":"10.1016\/j.jcyt.2026.102101_bib0006","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.761042","article-title":"\u201cHow long have I got?\u201d In stage IV NSCLC patients with at least 3 months up to 10 years survival, accuracy of long-, intermediate-, and short-term survival prediction is not good enough to answer this question","volume":"11","author":"Guo","year":"2021","journal-title":"Front Oncol"},{"issue":"7","key":"10.1016\/j.jcyt.2026.102101_bib0007","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1136\/thoraxjnl-2013-204110","article-title":"Systemic but not topical TRAIL-expressing mesenchymal stem cells reduce tumour growth in malignant mesothelioma","volume":"69","author":"Sage","year":"2014","journal-title":"Thorax"},{"issue":"10","key":"10.1016\/j.jcyt.2026.102101_bib0008","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1158\/0008-5472.CAN-08-4698","article-title":"Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer","volume":"69","author":"Loebinger","year":"2009","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.jcyt.2026.102101_bib0009","doi-asserted-by":"crossref","first-page":"273","DOI":"10.4048\/jbc.2012.15.3.273","article-title":"Stem cell implants for cancer therapy: TRAIL-expressing mesenchymal stem cells target cancer cells in situ","volume":"15","author":"Reagan","year":"2012","journal-title":"J Breast Cancer"},{"issue":"5","key":"10.1016\/j.jcyt.2026.102101_bib0010","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/j.1365-2141.2012.09082.x","article-title":"In vitro anti-myeloma activity of TRAIL-expressing adipose-derived mesenchymal stem cells","volume":"157","author":"Ciavarella","year":"2012","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.jcyt.2026.102101_bib0011","doi-asserted-by":"crossref","first-page":"4822","DOI":"10.1073\/pnas.0806647106","article-title":"Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy","volume":"106","author":"Sasportas","year":"2009","journal-title":"Proc Natl Acad Sci"},{"issue":"11","key":"10.1016\/j.jcyt.2026.102101_bib0012","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.molmed.2013.08.007","article-title":"TRAIL on trial: preclinical advances in cancer therapy","volume":"19","author":"Stuckey","year":"2013","journal-title":"Trends Mol Med"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102101_bib0013","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0022-3565(24)29298-3","article-title":"Preclinical studies to predict the disposition of Apo2L\/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety","volume":"299","author":"Kelley","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"10.1016\/j.jcyt.2026.102101_bib0014","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1172\/JCI6926","article-title":"Safety and antitumor activity of recombinant soluble Apo2 ligand","volume":"104","author":"Ashkenazi","year":"1999","journal-title":"J Clin Invest"},{"issue":"7","key":"10.1016\/j.jcyt.2026.102101_bib0015","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.jcyt.2015.03.603","article-title":"Mesenchymal stromal cell delivery of full-length tumor necrosis factor-related apoptosis-inducing ligand is superior to soluble type for cancer therapy","volume":"17","author":"Yuan","year":"2015","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102101_bib0016","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1186\/s13287-021-02609-x","article-title":"The safety of MSC therapy over the past 15 years: a meta-analysis","volume":"12","author":"Wang","year":"2021","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102101_bib0017","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S2213-2600(14)70291-7","article-title":"Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial","volume":"3","author":"Wilson","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcyt.2026.102101_bib0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1465-9921-15-39","article-title":"Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study","volume":"15","author":"Zheng","year":"2014","journal-title":"Respir Res"},{"issue":"10","key":"10.1016\/j.jcyt.2026.102101_bib0019","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.5966\/sctm.2015-0021","article-title":"In vivo effects of mesenchymal stromal cells in two patients with severe acute respiratory distress syndrome","volume":"4","author":"Simonson","year":"2015","journal-title":"Stem Cells Transl Med"},{"issue":"8","key":"10.1016\/j.jcyt.2026.102101_bib0020","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1164\/rccm.201001-0010OC","article-title":"Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis","volume":"182","author":"Mei","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.jcyt.2026.102101_bib0021","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1378\/chest.12-2094","article-title":"A placebo-controlled, randomized trial of mesenchymal stem cells in COPD","volume":"143","author":"Weiss","year":"2013","journal-title":"Chest"},{"issue":"33","key":"10.1016\/j.jcyt.2026.102101_bib0022","doi-asserted-by":"crossref","first-page":"14022","DOI":"10.1073\/pnas.0903201106","article-title":"Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity","volume":"106","author":"Quevedo","year":"2009","journal-title":"Proc Natl Acad Sci"},{"issue":"5","key":"10.1016\/j.jcyt.2026.102101_bib0023","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jacc.2011.09.065","article-title":"First experience in humans using adipose tissue\u2013derived regenerative cells in the treatment of patients with ST-segment elevation myocardial infarction","volume":"59","author":"Houtgraaf","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"10.1016\/j.jcyt.2026.102101_bib0024","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1093\/eurheartj\/eht372","article-title":"Impact of intracoronary bone marrow cell therapy on left ventricular function in the setting of ST-segment elevation myocardial infarction: a collaborative meta-analysis","volume":"35","author":"Delewi","year":"2014","journal-title":"Eur Heart J"},{"issue":"17","key":"10.1016\/j.jcyt.2026.102101_bib0025","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1093\/eurheartj\/ehm257","article-title":"Improved clinical outcome after intracoronary administration of bone marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial","volume":"28","author":"Marenzi","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcyt.2026.102101_bib0026","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s12885-015-1241-x","article-title":"Treatment of advanced gastrointestinal tumors with genetically modified autologous mesenchymal stromal cells (TREAT-ME1): study protocol of a phase I\/II clinical trial","volume":"15","author":"Niess","year":"2015","journal-title":"BMC Cancer"},{"issue":"46","key":"10.1016\/j.jcyt.2026.102101_bib0027","doi-asserted-by":"crossref","first-page":"80156","DOI":"10.18632\/oncotarget.20964","article-title":"Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells\u2014TREAT-ME-1: a phase I, first in human, first in class trial","volume":"8","author":"von Einem","year":"2017","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.jcyt.2026.102101_bib0028","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.jcyt.2016.09.003","article-title":"Genetically modified mesenchymal stromal cells in cancer therapy","volume":"18","author":"Sage","year":"2016","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102101_bib0029","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/s41598-018-37433-6","article-title":"Soluble TRAIL armed human MSC as gene therapy for pancreatic cancer","volume":"9","author":"Spano","year":"2019","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.jcyt.2026.102101_bib0030","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/scrt53","article-title":"Lentiviral vector mediated modification of mesenchymal stem cells & enhanced survival in an in vitro model of ischaemia","volume":"2","author":"McGinley","year":"2011","journal-title":"Stem Cell Res Ther"},{"issue":"3","key":"10.1016\/j.jcyt.2026.102101_bib0031","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nbt.2816","article-title":"Mesenchymal stem cells: immune evasive, not immune privileged","volume":"32","author":"Ankrum","year":"2014","journal-title":"Nat Biotechnol"},{"issue":"6","key":"10.1016\/j.jcyt.2026.102101_bib0032","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/sj.cgt.7701120","article-title":"Cisplatin enhances the antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand gene therapy via recruitment of the mitochondria-dependent death signaling pathway","volume":"15","author":"Shamimi-Noori","year":"2008","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.jcyt.2026.102101_bib0033","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10637-005-5854-9","article-title":"Histone deacetylase inhibitors interact synergistically with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis in carcinoma cell lines","volume":"23","author":"Sonnemann","year":"2005","journal-title":"Invest New Drugs"},{"issue":"16","key":"10.1016\/j.jcyt.2026.102101_bib0034","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1016\/j.ejca.2011.06.003","article-title":"Death receptor 5 and cellular FLICE-inhibitory protein regulate pemetrexed-induced apoptosis in human lung cancer cells","volume":"47","author":"Su","year":"2011","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.jcyt.2026.102101_bib0035","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.canlet.2010.01.005","article-title":"Synergistic antitumor effect of TRAIL in combination with sunitinib in vitro and in vivo","volume":"293","author":"Ding","year":"2010","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jcyt.2026.102101_bib0036","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-4598-9-87","article-title":"Doxorubicin and etoposide sensitize small cell lung carcinoma cells expressing caspase-8 to TRAIL","volume":"9","author":"Vaculova","year":"2010","journal-title":"Mol Cancer"},{"issue":"2","key":"10.1016\/j.jcyt.2026.102101_bib0037","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1158\/1535-7163.MCT-08-0918","article-title":"Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib","volume":"8","author":"Luster","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jcyt.2026.102101_bib0038","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/6810980","article-title":"Standardizing umbilical cord mesenchymal stromal cells for translation to clinical use: selection of GMP-compliant medium and a simplified isolation method","volume":"2016","author":"Smith","year":"2016","journal-title":"Stem Cells Int"},{"issue":"20","key":"10.1016\/j.jcyt.2026.102101_bib0039","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102101_bib0040","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/sctm.19-0202","article-title":"Trends in mesenchymal stem cell clinical trials 2004-2018: is efficacy optimal in a narrow dose range?","volume":"9","author":"Kabat","year":"2019","journal-title":"Stem Cells Transl Med"},{"issue":"3","key":"10.1016\/j.jcyt.2026.102101_bib0041","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102101_bib0042","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006072","article-title":"Venous thromboembolism incidence and risk factors associated with immune checkpoint inhibitors among patients with advanced non-small cell lung cancer","volume":"11","author":"Khorana","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"7","key":"10.1016\/j.jcyt.2026.102101_bib0043","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1016\/j.transproceed.2017.03.078","article-title":"Thromboembolism induced by umbilical cord mesenchymal stem cell infusion: a report of two cases and literature review","volume":"49","author":"Wu","year":"2017","journal-title":"Transpl Proc"},{"issue":"5","key":"10.1016\/j.jcyt.2026.102101_bib0044","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.3349\/ymj.2013.54.5.1293","article-title":"Familial occurrence of pulmonary embolism after intravenous, adipose tissue-derived stem cell therapy","volume":"54","author":"Jung","year":"2013","journal-title":"Yonsei Med J"},{"issue":"10","key":"10.1016\/j.jcyt.2026.102101_bib0045","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/sctm.18-0015","article-title":"Clinical cellular therapeutics accelerate clot formation","volume":"7","author":"George","year":"2018","journal-title":"Stem Cells Transl Med"},{"issue":"10","key":"10.1016\/j.jcyt.2026.102101_bib0046","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.3390\/cells8101160","article-title":"Thrombogenic risk induced by intravascular mesenchymal stem cell therapy: current status and future perspectives","volume":"8","author":"Coppin","year":"2019","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.jcyt.2026.102101_bib0047","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.bbrc.2012.12.134","article-title":"Tissue factor triggers procoagulation in transplanted mesenchymal stem cells leading to thromboembolism","volume":"431","author":"Tatsumi","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102101_bib0048","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/stcltm\/szab005","article-title":"Improved MSC minimal criteria to maximize patient safety: a call to embrace tissue factor and hemocompatibility assessment of MSC products","volume":"11","author":"Moll","year":"2022","journal-title":"Stem Cells Transl Med"},{"issue":"7","key":"10.1016\/j.jcyt.2026.102101_bib0049","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1002\/stem.1111","article-title":"Are therapeutic human mesenchymal stromal cells compatible with human blood?","volume":"30","author":"Moll","year":"2012","journal-title":"Stem Cells"},{"issue":"19","key":"10.1016\/j.jcyt.2026.102101_bib0050","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1089\/scd.2015.0120","article-title":"Different procoagulant activity of therapeutic mesenchymal stromal cells derived from bone marrow and placental decidua","volume":"24","author":"Moll","year":"2015","journal-title":"Stem Cells Dev"},{"issue":"6","key":"10.1016\/j.jcyt.2026.102101_bib0051","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1002\/ijc.32230","article-title":"Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells: results from the phase 1\/2 TREAT-ME-1 trial","volume":"145","author":"von Einem","year":"2019","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.jcyt.2026.102101_bib0052","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ccr.2011.08.010","article-title":"Mesenchymal stem cells induce resistance to chemotherapy through the release of platinum-induced fatty acids","volume":"20","author":"Roodhart","year":"2011","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102101_bib0053","doi-asserted-by":"crossref","DOI":"10.1186\/s13613-020-00741-0","article-title":"Pulmonary embolism in patients with coronavirus disease-2019 (COVID-19) pneumonia: a narrative review","volume":"10","author":"Sakr","year":"2020","journal-title":"Ann Intensive Care"},{"key":"10.1016\/j.jcyt.2026.102101_bib0054","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.thromres.2020.08.020","article-title":"Venous thromboembolism in patients with COVID-19: systematic review and meta-analysis","volume":"196","author":"Porfidia","year":"2020","journal-title":"Thromb Res"},{"key":"10.1016\/j.jcyt.2026.102101_bib0055","article-title":"Allogeneic umbilical cord-derived mesenchymal stromal cells as treatment for systemic lupus erythematosus: a single-centre, open-label, dose-escalation, phase 1 study","author":"Farge","year":"2024","journal-title":"Lancet Rheumatol"},{"issue":"6","key":"10.1016\/j.jcyt.2026.102101_bib0056","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jcyt.2024.03.076","article-title":"Allogeneic umbilical-cord derived mesenchymal stromal cells MSC(uc) as treatment for systemic lupus erythematosus (SLE): safety and early clinical\/biological results from a phase I-II proof-of-concept clinical study","volume":"26","author":"Farge","year":"2024","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102101_bib0057","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13287-020-01770-z","article-title":"Lung delivery of MSCs expressing anti-cancer protein TRAIL visualised with 89Zr-oxine PET-CT","volume":"11","author":"Patrick","year":"2020","journal-title":"Stem Cell Res Ther"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926000630?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926000630?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:05:02Z","timestamp":1777586702000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324926000630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1465324926000630"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102101","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A first-in-human phase I clinical trial investigating the safety and efficacy of repeat dosing MSCTRAIL cell therapy in addition to chemotherapy and immunotherapy in patients with advanced lung cancer","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102101","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102101"}}